- Home
- PRLD vs CGEN Comparison
PRLD vs CGEN Comparison
Compare PRLD & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | CGEN |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 188.2M |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PRLD | CGEN |
|---|---|---|
| Price | $4.39 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $4.67 | $4.00 |
| AVG Volume (30 Days) | 194.5K | ★ 223.6K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,140,000.00 | N/A |
| Revenue This Year | $320.10 | N/A |
| Revenue Next Year | $100.00 | $112.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 73.43 | N/A |
| 52 Week Low | $0.61 | $1.13 |
| 52 Week High | $4.19 | $2.38 |
Technical Indicators
Market Signals| Indicator | PRLD | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 72.26 | 63.15 |
| Support Level | $1.02 | $1.41 |
| Resistance Level | N/A | $2.35 |
| Average True Range (ATR) | 0.36 | 0.11 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 86.83 | 93.06 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.